A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT ID: NCT05508867
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
203 participants
INTERVENTIONAL
2022-10-18
2026-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
NCT03598608
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
NCT05008224
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
NCT02875067
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
NCT06504394
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
NCT02453594
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Favezelimab/Pembrolizumab
Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
favezelimab/pembrolizumab
Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
Chemotherapy (Bendamustine or Gemcitabine)
Participants will receive physician's choice of EITHER bendamustine by IV infusion at a dose between 90 and 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose between 800 and 1200 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
bendamustine
IV infusion
gemcitabine
IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
favezelimab/pembrolizumab
Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
bendamustine
IV infusion
gemcitabine
IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has relapsed (defined as disease progression after most recent therapy) or refractory (defined as failed to achieve CR or PR to most recent therapy) cHL and exhausted all available treatment options with known clinical benefit.
* Has progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies.
* Submits an archival (≤5 years) or newly obtained tumor tissue sample which has not been previously irradiated.
Exclusion Criteria
* History of central nervous system (CNS) metastases or active CNS involvement.
* Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy.
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* Has an active infection requiring systemic treatment.
* History of hemophagocytic lymphohisticytosis.
* Has an active seizure disorder that is not well controlled.
* Has clinically significant (ie, active) cardiovascular disease.
* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
* Received prior radiotherapy within 2 weeks of start of study intervention or radiation related toxicities requiring corticosteroids.
* Has not adequately recovered from major surgical procedure.
* Known additional malignancy that is progressing or has required active treatment within the past 3 years.
* History of human immunodeficiency virus (HIV).
* Has had an allogeneic hematopoietic stem cell or solid organ transplantation within the last 5 years.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Arizona Cancer Center - North Campus ( Site 2216)
Tucson, Arizona, United States
UCLA Hematology/Oncology - Santa Monica ( Site 2208)
Los Angeles, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site
Torrance, California, United States
Moffitt Cancer Center ( Site 2200)
Tampa, Florida, United States
University of Kentucky Chandler Medical Center ( Site 2201)
Lexington, Kentucky, United States
University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 2210)
Baltimore, Maryland, United States
Johns Hopkins University-The Sidney Kimmel Comprehensive Cancer Center ( Site 2206)
Baltimore, Maryland, United States
University of Michigan ( Site 2215)
Ann Arbor, Michigan, United States
Cancer and Hematology Centers of Western Michigan ( Site 2222)
Grand Rapids, Michigan, United States
Rutgers Cancer Institute of New Jersey ( Site 2217)
New Brunswick, New Jersey, United States
Roswell Park Cancer Institute ( Site 2220)
Buffalo, New York, United States
University Hospitals Cleveland Medical Center ( Site 2214)
Cleveland, Ohio, United States
Cleveland Clinic-Taussig Cancer Center ( Site 2203)
Cleveland, Ohio, United States
AHN West Penn Hospital ( Site 2213)
Pittsburgh, Pennsylvania, United States
UPMC Hillman Cancer Center ( Site 2205)
Pittsburgh, Pennsylvania, United States
Fred Hutchinson Cancer Center ( Site 2212)
Seattle, Washington, United States
Hospital Aleman-oncohematologic diseases ( Site 2302)
Buenos Aires, , Argentina
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 2301)
Mendoza, , Argentina
The Townsville Hospital ( Site 0006)
Townsville, Queensland, Australia
Royal Adelaide Hospital ( Site 0005)
Adelaide, South Australia, Australia
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0002)
St Albans, Victoria, Australia
Royal Perth Hospital-Haematology ( Site 0004)
Perth, Western Australia, Australia
UZ Leuven-Hematology ( Site 0101)
Leuven, Vlaams-Brabant, Belgium
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi
Namur, , Belgium
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0202)
Barretos, São Paulo, Brazil
Hospital Paulistano-Americas Oncologia ( Site 0207)
São Paulo, , Brazil
Cross Cancer Institute ( Site 0313)
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre ( Site 0310)
Toronto, Ontario, Canada
Jewish General Hospital ( Site 0309)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0314)
Montreal, Quebec, Canada
FALP-UIDO ( Site 0400)
Santiago, Region M. de Santiago, Chile
Clínica Inmunocel ( Site 0407)
Santiago, Region M. de Santiago, Chile
Anhui Provincial Cancer Hospital ( Site 0501)
Hefei, Anhui, China
Beijing Hospital ( Site 0514)
Beijing, Beijing Municipality, China
Peking University Third Hospital-Hematology ( Site 0519)
Beijing, Beijing Municipality, China
The First Affiliated hospital of Xiamen University ( Site 0512)
Xiamen, Fujian, China
Sun Yat-sen University Cancer Center ( Site 0500)
Guangzhou, Guangdong, China
Henan Cancer Hospital ( Site 0515)
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0509)
Wuhan, Hubei, China
Xiangya Hospital Central South University ( Site 0513)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 0503)
Changsha, Hunan, China
The First Hospital of Jilin University-Hematology ( Site 0516)
Changchun, Jilin, China
Fudan University Shanghai Cancer Center ( Site 0520)
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University-Head and Neck Oncology ( Site 0502)
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 0506)
Tianjin, Tianjin Municipality, China
Zhejiang Cancer Hospital ( Site 0510)
Hangzhou, Zhejiang, China
Ningbo First Hospital ( Site 0518)
Ningbo, Zhejiang, China
Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0901)
Brno, Brno-mesto, Czechia
Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0902)
Hradec Králové, , Czechia
Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0903)
Prague, , Czechia
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou-haematology ( Site 0707)
Rennes, Brittany Region, France
Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE ( Site 0706)
Toulouse, Haute-Garonne, France
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 0704)
Limoges, Haute-Vienne, France
Institut Curie - site Saint-Cloud ( Site 0708)
Saint-Cloud, Hauts-de-Seine, France
CENTRE LEON BERARD-Medical oncology ( Site 0703)
Lyon, Rhone, France
HENRI MONDOR HOSPITAL ( Site 0702)
Créteil, Seine-et-Marne, France
Klinikum Stuttgart - Katharinenhospital ( Site 0804)
Stuttgart, Baden-Wurttemberg, Germany
Universitaetsklinikum Ulm-Department of Internal Medicine III ( Site 0805)
Ulm, Baden-Wurttemberg, Germany
Universitaetsklinikum Koeln-Klinik I für Innere Medizin ( Site 0801)
Cologne, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen ( Site 0807)
Essen, North Rhine-Westphalia, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus ( Site 0806)
Münster, North Rhine-Westphalia, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit (
Dresden, Saxony, Germany
Universitätsklinikum Leipzig ( Site 0803)
Leipzig, Saxony, Germany
Rambam Health Care Campus ( Site 1004)
Haifa, , Israel
Carmel Hospital ( Site 1007)
Haifa, , Israel
Hadassah Medical Center-Hemato-Oncology ( Site 1000)
Jerusalem, , Israel
Rabin Medical Center-Hemato-Oncology ( Site 1001)
Petah Tikva, , Israel
Sheba Medical Center-Hemato Oncology ( Site 1005)
Ramat Gan, , Israel
Sourasky Medical Center ( Site 1002)
Tel Aviv, , Israel
Centro de Infusion Superare ( Site 2503)
Mexico City, Mexico City, Mexico
Unidad Médica Onco-hematológica ( Site 2507)
Puebla City, , Mexico
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1406)
Krakow, Lesser Poland Voivodeship, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckieg-Klinika Hematologii, Nowotworów Krwi i
Wroclaw, Lower Silesian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 1402)
Gdansk, Pomeranian Voivodeship, Poland
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S
Kielce, Świętokrzyskie Voivodeship, Poland
Pusan National University Hospital-Internal Medicine ( Site 1704)
Busan, Pusan-Kwangyokshi, South Korea
Seoul National University Hospital ( Site 1701)
Seoul, , South Korea
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1702)
Seoul, , South Korea
Asan Medical Center-Department of Oncology ( Site 1703)
Seoul, , South Korea
Samsung Medical Center ( Site 1700)
Seoul, , South Korea
Hospital Universitario Marqués de Valdecilla ( Site 1805)
Santander, Cantabria, Spain
Hospital Universitari Vall d'Hebron ( Site 1803)
Barcelona, Catalonia, Spain
CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 1812)
A Coruña, La Coruna, Spain
Hospital Insular de Gran Canaria-Oncology ( Site 1807)
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital General Universitario de Alicante ( Site 1806)
Alicante, , Spain
Hospital Universitario 12 de Octubre-Hemathology and hemotherapy ( Site 1810)
Madrid, , Spain
Hospital Universitario Virgen de la Victoria ( Site 1808)
Málaga, , Spain
Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 1801)
Salamanca, , Spain
Skånes Universitetssjukhus Lund ( Site 1901)
Lund, Skåne County, Sweden
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1900)
Uppsala, Uppsala County, Sweden
Ospedale Regionale Bellinzona e Valli-IOSI ( Site 1600)
Bellinzona, Canton Ticino, Switzerland
Mega Medipol-Hematology ( Site 2005)
Stanbul, Istanbul, Turkey (Türkiye)
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 2000)
Ankara, , Turkey (Türkiye)
Hacettepe Universite Hastaneleri-Department of Hematology ( Site 2006)
Ankara, , Turkey (Türkiye)
Antalya Egitim ve Arastırma Hastanesi ( Site 2011)
Antalya, , Turkey (Türkiye)
Ege Universitesi Hastanesi ( Site 2001)
Izmir, , Turkey (Türkiye)
Kocaeli Üniversitesi-Hematology ( Site 2009)
Kocaeli, , Turkey (Türkiye)
Derriford Hospital ( Site 2107)
Plymouth, Devon, United Kingdom
The Beatson West of Scotland Cancer Centre ( Site 2110)
Glasgow, Glasgow City, United Kingdom
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 2105)
London, London, City of, United Kingdom
GenesisCare - Oxford ( Site 2104)
Oxford, Oxfordshire, United Kingdom
St James's University Hospital ( Site 2109)
Leeds, , United Kingdom
Leicester Royal Infirmary ( Site 2100)
Leicester, , United Kingdom
Clatterbridge Cancer Centre - Liverpool-Heamatology ( Site 2108)
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-4280A-008
Identifier Type: OTHER
Identifier Source: secondary_id
2023-503615-14-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1287-5864
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022-000371-39
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
4280A-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.